Research outlook

Where type 2 diabetes treatment is heading

Type 2 diabetes · Updated Nov 15, 2026

About 38 million Americans have diabetes, and more than 9 in 10 have type 2. Metformin is still common first, but treatment now centers on drugs that also protect the heart and kidneys: GLP-1 drugs such as semaglutide, dual GIP/GLP-1 tirzepatide, SGLT2 inhibitors, and finerenone for kidney disease. Research is racing toward stronger weight-and-sugar drugs (triple-hormone and amylin drugs), easier forms (GLP-1 pills, monthly shots, weekly insulin), and drugs that protect organs directly.

  1. Now

    Nov 2026

    GLP-1 pills without food rulesHappened 1.91 point drop in HbA1c

    Orforglipron lowered HbA1c by 1.91 points vs 1.47 with oral semaglutide over a year.

    1.91: percentage-point drop in HbA1c with orforglipron 36 mg, vs 1.47 with semaglutide 14 mg.

    Triple-hormone and amylin drugsHappened 15.3% weight loss

    Retatrutide cut weight 15.3% and CagriSema 13.7% in type 2 diabetes, with large HbA1c drops.

    15.3%: weight loss with retatrutide 12 mg, vs 2.6% with placebo.

    Heart and kidney protectionHappened 24% fewer kidney events

    Semaglutide cut major kidney events by 24%; tirzepatide matched dulaglutide for heart protection; starting finerenone and empagliflozin together cut kidney protein loss further.

    24%: lower risk of major kidney events with semaglutide.

  2. 6 months

    by May 2027

    Retatrutide head to headLikely 15.3% weight loss vs placebo

    Lilly's TRANSCEND-T2D-2 (1,250 people) compares retatrutide with semaglutide; its main analysis was due August 2026.

    15.3%: weight loss with retatrutide 12 mg, vs 2.6% with placebo.

    A once-monthly injectionLikely

    Amgen's MARITIME-2 (1,105 people) tests monthly maridebart cafraglutide in type 2 diabetes with overweight; due January 2027.

  3. 12 months

    by Nov 2027

    Does semaglutide affect the eyes?Possible

    Novo Nordisk's FOCUS (1,500 people) tests semaglutide's effect on diabetic eye disease over 5 years; due November 2027.

    More GLP-1 optionsPossible

    Viking's VANQUISH 2 (1,100 people, due July 2027) tests VK2735 in type 2 diabetes with obesity.

  4. 3 years

    by late 2029

    A wave of new pills and shotsPossible

    AstraZeneca's elecoglipron pill (Eluminate trials), Novo's zenagamtide (AMBITION) and Roche's enicepatide (Enith) report in 2028.

    Amylin drugs for diabetesPossible 13.7% weight loss (CagriSema)

    Lilly's eloralintide (ENLIGHTEN-2, due January 2028) and higher-dose CagriSema (due February 2028) test amylin-based weight and sugar control.

    13.7%: weight loss with CagriSema, vs 3.4% with placebo.

  5. 5 years

    by late 2031

    Blocking aldosterone to protect the heartPossible

    Boehringer's EASi-PROTKT (11,800 people, due December 2029) tests vicadrostat with empagliflozin for heart outcomes in diabetes with high blood pressure.

    Weekly insulin becomes routineLong shot 2 dose changes a year

    With fixed-dose weekly insulins as effective as daily insulin, fewer injections and simpler dosing could become standard.

    2: dose changes needed in a year, vs 8 with daily glargine (median).

Happened Likely Possible Long shot

The research paths

Heating up

Stronger hormone drugs

15.3% weight loss
Details and 9 trialsHide
Heating up

Pills instead of shots

1.91 point drop in HbA1c
Details and 3 trialsHide
Maturing

Protecting heart, kidneys and eyes

24% fewer kidney events
Details and 2 trialsHide
Maturing

Simpler insulin

2 dose changes a year
DetailsHide

Once-weekly basal insulins with fewer dose changes and less serious low blood sugar.

WatchApprovals and real-world use.

Borrowed from other conditions

From Hypertension and kidney disease

Vicadrostat

Phase 3

An aldosterone synthase inhibitor, the same class as baxdrostat for resistant high blood pressure.

From Kidney transplant rejection

Clazakizumab

Phase 2

An IL-6 antibody being tested to lower inflammation and heart risk in people with raised hsCRP.

Open to join now

See every recruiting Type 2 diabetes trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
Aug 2026
Jan 2027
VK2735 (VANQUISH 2)Pills instead of shots
Jul 2027
Semaglutide and diabetic eye disease (FOCUS)Protecting heart, kidneys and eyes
Nov 2027
Jan 2028
Survodutide for blood sugarStronger hormone drugs
Jan 2028
Feb 2028
May 2028
Jul 2028
Enicepatide (Enith1)Stronger hormone drugs
Jul 2028
Jul 2028
Dec 2028
Dec 2029

What just happened

Retatrutide lowers HbA1c and weight in early type 2 diabetes

TRANSCEND-T2D-1, The Lancet.

Orforglipron beats oral semaglutide on HbA1c

ACHIEVE-3, The Lancet.

Tirzepatide matches dulaglutide on heart outcomes

SURPASS-CVOT, NEJM.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See Type 2 diabetes trials recruiting now →

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.